Scheifele M, Gnorich J, Schroder E, Kunte S, Ells Z, Hagen J
Eur J Nucl Med Mol Imaging. 2025; .
PMID: 40064709
DOI: 10.1007/s00259-025-07188-0.
Quinones A, Vieira L, Wang J
Drug Metab Dispos. 2022; 50(9).
PMID: 35197314
PMC: 9488973.
DOI: 10.1124/dmd.121.000707.
van Nuland M, Ververs T, Lam M
Int J Mol Sci. 2022; 23(2).
PMID: 35055005
PMC: 8775906.
DOI: 10.3390/ijms23020818.
Lokitz S, Garg S, Nazih R, Garg P
Mol Imaging Biol. 2018; 21(4):686-695.
PMID: 30250991
DOI: 10.1007/s11307-018-1280-1.
Kayano D, Kinuya S
Nucl Med Mol Imaging. 2018; 52(4):254-265.
PMID: 30100938
PMC: 6066492.
DOI: 10.1007/s13139-018-0523-z.
MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies.
Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N
Br J Radiol. 2018; 91(1091):20180103.
PMID: 30048149
PMC: 6475939.
DOI: 10.1259/bjr.20180103.
Guidelines on nuclear medicine imaging in neuroblastoma.
Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman M, Lopci E
Eur J Nucl Med Mol Imaging. 2018; 45(11):2009-2024.
PMID: 29938300
DOI: 10.1007/s00259-018-4070-8.
Theranostics in nuclear medicine practice.
Yordanova A, Eppard E, Kurpig S, Bundschuh R, Schonberger S, Gonzalez-Carmona M
Onco Targets Ther. 2017; 10:4821-4828.
PMID: 29042793
PMC: 5633297.
DOI: 10.2147/OTT.S140671.
Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease.
Oh J, Choi E, Song I, Kim J, Chung Y
J Neural Transm (Vienna). 2015; 122(10):1421-7.
PMID: 26003179
DOI: 10.1007/s00702-015-1409-1.
Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.
Kayano D, Kinuya S
ScientificWorldJournal. 2015; 2015:189135.
PMID: 25874239
PMC: 4385691.
DOI: 10.1155/2015/189135.
Molecular imaging in heart failure patients.
Tamaki N, Kuge Y, Yoshinaga K
Clin Transl Imaging. 2014; 1:341-351.
PMID: 24765617
PMC: 3991005.
DOI: 10.1007/s40336-013-0034-y.
A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging.
Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S
Eur J Nucl Med Mol Imaging. 2014; 41(9):1673-82.
PMID: 24663289
PMC: 4122818.
DOI: 10.1007/s00259-014-2759-x.
Targeted radionuclide therapy.
Ersahin D, Doddamane I, Cheng D
Cancers (Basel). 2013; 3(4):3838-55.
PMID: 24213114
PMC: 3763399.
DOI: 10.3390/cancers3043838.
Simultaneous 99mTc-MDP/123I-MIBG tumor imaging using SPECT-CT: phantom and constructed patient studies.
Rakvongthai Y, El Fakhri G, Lim R, Bonab A, Ouyang J
Med Phys. 2013; 40(10):102506.
PMID: 24089927
PMC: 3785531.
DOI: 10.1118/1.4820977.
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.
Gimm O, DeMicco C, Perren A, Giammarile F, Walz M, Brunaud L
Langenbecks Arch Surg. 2011; 397(2):155-77.
PMID: 22124609
DOI: 10.1007/s00423-011-0880-x.
[Clinical and imaging diagnostics of Parkinson's disease and multiple system atrophy].
Schmidt K, Spiegel J, Reith W
Radiologe. 2011; 51(4):273-7.
PMID: 21431458
DOI: 10.1007/s00117-010-2095-5.
Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease.
Spiegel J
Parkinsons Dis. 2010; 2010:295346.
PMID: 20975774
PMC: 2956969.
DOI: 10.4061/2010/295346.
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J
Pediatr Blood Cancer. 2010; 56(2):191-201.
PMID: 20830775
PMC: 3006009.
DOI: 10.1002/pbc.22767.
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.
Bombardieri E, Giammarile F, Aktolun C, Baum R, Bischof Delaloye A, Maffioli L
Eur J Nucl Med Mol Imaging. 2010; 37(12):2436-46.
PMID: 20644928
DOI: 10.1007/s00259-010-1545-7.
The radiation burden of radiological investigations.
Mazrani W, McHugh K, Marsden P
Arch Dis Child. 2007; 92(12):1127-31.
PMID: 18032642
PMC: 2066089.
DOI: 10.1136/adc.2006.101782.